TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25134002

Group type: EXPERIMENTAL
Intervention: Caffeine 3 mg·kg body mass
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Caffeine 4.5 mg·kg body mass
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 8
Study: 22446674

Group type: EXPERIMENTAL
Intervention: Nintendo Wii Fit 'Free Run' program
Number of subjects: 21

Group type: COMPARATOR
Intervention: Treadmill brisk walking
Number of subjects: 21
Study: 19139296

Group type: EXPERIMENTAL
Intervention: Animal models of SCN1A mutants
Number of subjects: 0
Study: 17672892

Group type: EXPERIMENTAL
Intervention: Peer support intervention with trained peer supporters conducting nine group meetings over two years.
Number of subjects: 420

Group type: COMPARATOR
Intervention: Standardised diabetes care system (Control group).
Number of subjects: 420
Study: 14715864

Group type: EXPERIMENTAL
Intervention: Glibenclamide (10.5 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Repaglinide (8 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Glibenclamide and Repaglinide
Number of subjects: 10
Study: 11768836

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 728

Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 728

Group type: EXPERIMENTAL
Intervention: Both
Number of subjects: 728
Study: 9400356

Group type: EXPERIMENTAL
Intervention: Interferon beta-1b
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control
Number of subjects: 79
Study: 8214179

Group type: EXPERIMENTAL
Intervention: Group psychotherapy (90-minute weekly sessions for 10 weeks)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no group psychotherapy)
Number of subjects: 48
Study: 3304367

Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg/day
Number of subjects: 9

Group type: COMPARATOR
Intervention: Nifedipine 20 mg three times a day
Number of subjects: 9

Group type: COMPARATOR
Intervention: Isosorbide mononitrate 40 mg twice a day
Number of subjects: 9
Study: 30003027

Group type: EXPERIMENTAL
Intervention: S-Ketamine (initial bolus 1 mg/kg and continuous infusion of 0.015625 mg/kg/min with dosage reduction -10%/10 min)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 17
Study: 27043952

Group type: EXPERIMENTAL
Intervention: Trauma-Focused Cognitive Behavioral Therapy (Tf-CBT)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Waiting List (WL)
Number of subjects: 159
Study: 24878085

Group type: EXPERIMENTAL
Intervention: Chemotherapy + metformin (850 mg three times a day)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Standard chemotherapy
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Chemotherapy + metformin
Number of subjects: 93
Study: 23869890

Group type: EXPERIMENTAL
Intervention: Lower body positive pressure (LBPP) at 20 mm Hg
Number of subjects: 1

Group type: COMPARATOR
Intervention: Control (no LBPP)
Number of subjects: 1
Study: 20848899

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) of Sanyinjiao (SP 6)
Number of subjects: 349

Group type: COMPARATOR
Intervention: Sham‐EA
Number of subjects: 349

Group type: COMPARATOR
Intervention: Control
Number of subjects: 349
Study: 18047502

Group type: EXPERIMENTAL
Intervention: BoNTA 100 U
Number of subjects: 59

Group type: COMPARATOR
Intervention: DVPX 250 mg
Number of subjects: 59
Study: 16815783

Group type: EXPERIMENTAL
Intervention: fat + caffeine trial
Number of subjects: 18
Study: 12829154

Group type: EXPERIMENTAL
Intervention: RT plus amifostine (340 mg/m2 i.v., 15 min before RT)
Number of subjects: 205

Group type: COMPARATOR
Intervention: RT
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: RT plus amifostine
Number of subjects: 205
Study: 10217382

Group type: EXPERIMENTAL
Intervention: Health care interventions evaluated in the trials; specific interventions not detailed.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable; control group details not provided.
Number of subjects: 0
Study: 7792744

Group type: EXPERIMENTAL
Intervention: Maximal exercise test
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Anaerobic threshold exercise test
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Aerobic threshold exercise test
Number of subjects: 9
Study: 2143638

Group type: EXPERIMENTAL
Intervention: Epidural sufentanil 25 micrograms plus clonidine 1 microgram/kg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Epidural sufentanil 50 micrograms alone
Number of subjects: 40
Study: 7438385

Group type: EXPERIMENTAL
Intervention: Naloxone 0.2 mg/kg over 1 minute
Number of subjects: 7

Group type: COMPARATOR
Intervention: Volume‐matched saline (placebo)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 7
Study: 30873906

Group type: EXPERIMENTAL
Intervention: Interactive web-based platform combining network meta-analysis findings with patient preferences
Number of subjects: 349

Group type: COMPARATOR
Intervention: Series of bar charts (control)
Number of subjects: 349
Study: 29891906

Group type: EXPERIMENTAL
Intervention: Natural hirudin and subcutaneous LMWH-calcium (test group)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Subcutaneous LMWH-calcium (control group)
Number of subjects: 96
Study: 27271683

Group type: EXPERIMENTAL
Intervention: Goals of care decision aid intervention (video decision aid and structured discussion); delivered ideally within 3 months after viewing.
Number of subjects: 151
Study: 25473882

Group type: EXPERIMENTAL
Intervention: GSK1265744 (744) LA 800 mg IM followed by 3 monthly doses of 200 mg subcutaneously
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: GSK1265744 (744) LA 800 mg IM followed by 3 monthly doses of 200 mg IM
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: GSK1265744 (744) LA 800 mg IM followed by 3 monthly doses of 400 mg IM
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: GSK1265744 (744) LA 800 mg IM followed by a second injection of 800 mg IM after 12 weeks
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Rilpivirine (RPV) LA 1200 mg IM at month 3 and 900 or 600 mg IM at month 4
Number of subjects: 47
Study: 21904833

Group type: EXPERIMENTAL
Intervention: AFI (Autofluorescence Imaging)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: HRE (High Resolution Endoscopy)
Number of subjects: 94

Group type: COMPARATOR
Intervention: AFI
Number of subjects: 94

Group type: COMPARATOR
Intervention: HRE
Number of subjects: 94

Group type: COMPARATOR
Intervention: AFI alone
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: NBI (Narrow Band Imaging)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Combined AFI and NBI
Number of subjects: 94
Study: 20724650

Group type: EXPERIMENTAL
Intervention: Neck circumference measurement
Number of subjects: 3182

Group type: EXPERIMENTAL
Intervention: Neck circumference cutoff points
Number of subjects: 3182

Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic analysis
Number of subjects: 3182
Study: 18417444

Group type: EXPERIMENTAL
Intervention: Internet-based dyspnea self-management program (eDSMP)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Face-to-face dyspnea self-management program (fDSMP)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both programs (eDSMP and fDSMP)
Number of subjects: 50
Study: 15838676

Group type: EXPERIMENTAL
Intervention: Neonatal helmet CPAP
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nasal CPAP
Number of subjects: 20
Study: 11842363

Group type: EXPERIMENTAL
Intervention: 7.6% glucose drink
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 10756890

Group type: EXPERIMENTAL
Intervention: Advice about sodium restriction, weight reduction, physical exercise, relaxation, and a diet rich in fruits, vegetables, and low-fat dairy foods.
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Community studies with prevention interventions on entire populations.
Number of subjects: 6
Study: 7709275

Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Lignocaine
Number of subjects: 50
Study: 2284386

Group type: EXPERIMENTAL
Intervention: Oestrogen challenge with ethinyl oestradiol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patients with anorexia nervosa
Number of subjects: 0
Study: 467112

Group type: EXPERIMENTAL
Intervention: Nasotracheal suctioning
Number of subjects: 21
Study: 6763435

Group type: EXPERIMENTAL
Intervention: Oral prednisone, 10 mg thrice daily, continued until clinical remission, maximally 12 weeks.
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 30150128

Group type: EXPERIMENTAL
Intervention: Family-based intervention by pharmacists
Number of subjects: 196

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 196
Study: 29436064

Group type: EXPERIMENTAL
Intervention: 5 mg of amitriptyline at bedtime for 2 months
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo pill
Number of subjects: 220
Study: 27161894

Group type: EXPERIMENTAL
Intervention: Cholecalciferol (50,000 IU twice weekly)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo (50 drops of a placebo solution twice weekly)
Number of subjects: 38
Study: 25604219

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 108

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 108
Study: 22457014

Group type: EXPERIMENTAL
Intervention: Salbutamol (400 μg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ipratropium (80 μg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 19814602

Group type: EXPERIMENTAL
Intervention: Physical activity maintenance intervention
Number of subjects: 377
Study: 17645712

Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 29
Study: 16042675

Group type: EXPERIMENTAL
Intervention: Gemfibrozil (600 mg) and Itraconazole (100 mg, first dose 200 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 12353302

Group type: EXPERIMENTAL
Intervention: 1 mg daily warfarin
Number of subjects: 98

Group type: COMPARATOR
Intervention: Variable dose warfarin (PT 1.3‐1.5 times the normal PT)
Number of subjects: 98
Study: 10419991

Group type: EXPERIMENTAL
Intervention: Prenatal supplements containing iron + folate + zinc (15 mg zinc)
Number of subjects: 1295

Group type: COMPARATOR
Intervention: Prenatal supplements containing iron + folate (without zinc)
Number of subjects: 1295

Group type: EXPERIMENTAL
Intervention: Both groups (zinc and no zinc)
Number of subjects: 1295
Study: 7480534

Group type: EXPERIMENTAL
Intervention: Capsule associated with high frequency of reinforcement (greater monetary payoff)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Capsule associated with low frequency of reinforcement (lower monetary payoff)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Self-administration results
Number of subjects: 12
Study: 2124648

Group type: EXPERIMENTAL
Intervention: Piperazine oestrone sulphate (PE1S, 2.5 mg/day)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Oestradiol valerate (E2V, 2.0 mg/day)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: PE1S in combination with levonorgestrel (LNG, 250 micrograms/day)
Number of subjects: 8

Group type: COMPARATOR
Intervention: E2V
Number of subjects: 8
Study: 6770707

Group type: EXPERIMENTAL
Intervention: Oral sodium cromoglycate (200 mg four times daily for 4 weeks)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Oral sodium cromoglycate
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Neither
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Clinician preference
Number of subjects: 15
Study: 30039199

Group type: EXPERIMENTAL
Intervention: Cilostazol 100 mg oral dose
Number of subjects: 33
Study: 28616765

Group type: EXPERIMENTAL
Intervention: 150 g kg‐1 RSM
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: 450 g kg‐1 RSM
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: 600 g kg‐1 RSM
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: 450 g kg‐1 RSM and 600 g kg‐1 RSM
Number of subjects: 125
Study: 26222270

Group type: EXPERIMENTAL
Intervention: Treatment aiming at normoglycemia (n = 33)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Routine care (Control group, n = 36)
Number of subjects: 69
Study: 23537332

Group type: EXPERIMENTAL
Intervention: Telemonitoring intervention (daily self-measurements of respiratory-rate, heart-rate, blood pressure, oxygen saturation, weight, body temperature, and health status questionnaire)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Telemonitoring intervention
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 58
Study: 21414332

Group type: COMPARATOR
Intervention: High frequency rTMS of the right DLPFC
Number of subjects: 28
Study: 18190554

Group type: EXPERIMENTAL
Intervention: 0.1% w/w cetylpyridinium chloride (CPC) mouthwash (B)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 0.05% w/w CPC mouthwash (A)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo mouthwash (C)
Number of subjects: 32
Study: 16860830

Group type: EXPERIMENTAL
Intervention: DEC alone (6 mg/kg)
Number of subjects: 47

Group type: COMPARATOR
Intervention: DEC and albendazole (400 mg)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: DEC alone (6 mg/kg) and DEC and albendazole (400 mg)
Number of subjects: 47
Study: 12707148

Group type: EXPERIMENTAL
Intervention: Active warming of the upper abdomen with a carbon‐fiber warming blanket (42 degrees C)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No warming of the abdomen
Number of subjects: 60
Study: 11279354

Group type: EXPERIMENTAL
Intervention: Internal globus pallidus (GPi) stimulation
Number of subjects: 7
Study: 9377176

Group type: EXPERIMENTAL
Intervention: Electrical stimulation of the tibial nerve during the last third of the first step stance phase with trains of five rectangular pulses, 1 ms in duration, at 20 Hz.
Number of subjects: 5

Group type: COMPARATOR
Intervention: No electrical stimulation (control condition).
Number of subjects: 5
Study: 8311536

Group type: EXPERIMENTAL
Intervention: 2 mg oestradiol-valerate
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 3013044

Group type: EXPERIMENTAL
Intervention: Fentanyl (0.005 mg/kg b.w.)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Buprenorphine (0.01 mg/kg b.w.)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combination of fentanyl and buprenorphine
Number of subjects: 30
Study: 31707570

Group type: EXPERIMENTAL
Intervention: LSG with antrectomy (2 cm to pylorus)
Number of subjects: 127

Group type: COMPARATOR
Intervention: LSG without antrectomy (6 cm to pylorus)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Comparison of group 1 (LSG with antrectomy) and group 2 (LSG without antrectomy)
Number of subjects: 127
Study: 29912266

Group type: EXPERIMENTAL
Intervention: Monthly active asking
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Daily self-report diary entries
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Call-in hotline
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Combination of active asking and diaries
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Combination of active asking and hotline
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Active asking vs diary entries
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Fall rates
Number of subjects: 373
Study: 28407657

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids and vitamin E co-supplementation (1,000 mg omega-3 from flaxseed oil containing 400 mg α-Linolenic acid plus 400 IU vitamin E)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids and vitamin E co-supplementation
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 25744115

Group type: EXPERIMENTAL
Intervention: Exenatide once weekly (2 mg)
Number of subjects: 258
Study: 23748748

Group type: EXPERIMENTAL
Intervention: Ritonavir (0.1-300 mg)
Number of subjects: 12
Study: 19912513

Group type: EXPERIMENTAL
Intervention: Oral vitamin K (1 mg) on the day before surgery (group K)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Heparin bridging after the last VKA dose on day -5 before surgery (group H)
Number of subjects: 94
Study: 19080512

Group type: EXPERIMENTAL
Intervention: Labor analgesia with ropivacaine
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control group (no pain relieving measure)
Number of subjects: 124
Study: 16856145

Group type: COMPARATOR
Intervention: Rasagiline (1 mg/2 mg); n = 38
Number of subjects: 110

Group type: COMPARATOR
Intervention: Rasagiline (0.5 mg/day); n = 22
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo; n = 21
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Rasagiline (1 mg/day); n = 12
Number of subjects: 110
Study: 12496956

Group type: EXPERIMENTAL
Intervention: Oxytocin infusion
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 15
Study: 10906651

Group type: EXPERIMENTAL
Intervention: Pulsed-dye laser (PDL) therapy (585 nm)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional therapy (liquid nitrogen cryotherapy or cantharidin)
Number of subjects: 40
Study: 8854792

Group type: EXPERIMENTAL
Intervention: Continuous hyperthermic pleural perfusion (CHPP) with 100 mg CDDP diluted in saline
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Continuous hyperthermic pleural perfusion (CHPP) with 100 mg CDDP diluted in distilled water
Number of subjects: 9
Study: 1471663

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (6 gm intravenous bolus)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 6443596

Group type: EXPERIMENTAL
Intervention: 15 micrograms/kg alfentanil
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 30 micrograms/kg alfentanil
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 5 micrograms/kg fentanyl
Number of subjects: 50

Group type: COMPARATOR
Intervention: 1 ml/20 kg saline (Control)
Number of subjects: 50
Study: 29732952

Group type: EXPERIMENTAL
Intervention: Deep circumflex iliac artery flap
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Fibular flap
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Scapular flap
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Iliac crest osseal flap
Number of subjects: 163
Study: 30588947

Group type: EXPERIMENTAL
Intervention: Combined intrarectal lidocaine gel and periprostatic nerve block (cGPNB)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Caudal block (CB)
Number of subjects: 109
Study: 27154849

Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Standard oxygen therapy
Number of subjects: 17
Study: 25218139

Group type: EXPERIMENTAL
Intervention: Vibration (experimental group)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (no vibration)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sham control (ultrasound vibration)
Number of subjects: 90
Study: 21884013

Group type: EXPERIMENTAL
Intervention: Ambrisentan 5 mg once daily for 24 weeks
Number of subjects: 224
Study: 20580035

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (10 mg/d) for 20 weeks
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Rosuvastatin/exercise (10 mg/d + exercise training 3d/wk from week 10 to week 20)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (10 mg/d) and Rosuvastatin/exercise (10 mg/d + exercise training) combined
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (physically active hypercholesterolemic subjects)
Number of subjects: 33
Study: 18007551

Group type: EXPERIMENTAL
Intervention: Metformin 500mg tid for 6 months
Number of subjects: 25

Group type: COMPARATOR
Intervention: Lifestyle interventions (disease controls)
Number of subjects: 25
Study: 16121967

Group type: EXPERIMENTAL
Intervention: Clazosentan (0.2 mg/kg/hr)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Clazosentan (0.4 mg/kg/hr for 12 hours followed by 0.2 mg/kg/hr)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Clazosentan
Number of subjects: 34
Study: 11835038

Group type: COMPARATOR
Intervention: Placebo treatment for 14 days
Number of subjects: 833
Study: 10999124

Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (400 mg/day for six weeks) in Group I
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Vitamin E levels in Group I
Number of subjects: 34

Group type: COMPARATOR
Intervention: Vitamin E levels in Group II
Number of subjects: 34

Group type: COMPARATOR
Intervention: Lipid peroxide levels in Group II
Number of subjects: 34
Study: 7588587

Group type: EXPERIMENTAL
Intervention: Well-controlled epilepsy
Number of subjects: 494

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 494
Study: 1524655

Group type: EXPERIMENTAL
Intervention: Haloperidol (0.5 mg/kg)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Reduced haloperidol (0.5 mg/kg)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Haloperidol (10 mg) twice daily for 4 weeks
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: N‐dealkylation pathway
Number of subjects: 7
Study: 3886566

Group type: EXPERIMENTAL
Intervention: Diltiazem alone
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Diltiazem in combination with diuretics
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Diltiazem in combination with other drugs
Number of subjects: 70
Study: 31295074

Group type: EXPERIMENTAL
Intervention: Biofilm-disrupting gel (BlastX) plus debridement (standard of care)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Triple-antibiotic maximum-strength ointment (standard of care)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Crossover to biofilm-disrupting gel after 4 weeks of standard care
Number of subjects: 0
Study: 27655525

Group type: EXPERIMENTAL
Intervention: Mashed potato with broccoli
Number of subjects: 13

Group type: COMPARATOR
Intervention: Mashed potato alone
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Mashed potato with broccoli fibre
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Mashed potato with cellulose
Number of subjects: 13
Study: 27258230

Group type: EXPERIMENTAL
Intervention: cART
Number of subjects: 215
Study: 25293665

Group type: EXPERIMENTAL
Intervention: Transcranial laser therapy
Number of subjects: 566

Group type: COMPARATOR
Intervention: Sham (control)
Number of subjects: 566
Study: 22240359

Group type: EXPERIMENTAL
Intervention: Rheohaemapheresis (separator Cobe Spectra + Evaflux filter)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 72